Compare Stocks: OGN, ELAN, CORT, and AXSM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$210.68 +0.0%	$221.78	$112.90 ▼ $260.19	$11.03B	0.71	743,538 shs	73,270 shs
CORT Corcept Therapeutics	$115.65 0.0%	$105.69	$28.66 ▼ $126.38	$12.52B	0.45	1.48 million shs	84,991 shs
ELAN Elanco Animal Health	$23.23 -1.4%	$24.61	$18.22 ▼ $27.98	$11.59B	1.68	5.62 million shs	659,539 shs
OGN Organon & Co.	$13.66 -0.1%	$13.63	$5.69 ▼ $13.78	$3.59B	1.52	5.60 million shs	432,219 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	+1.35%	+0.34%	-4.64%	-17.00%	+67.59%
CORT Corcept Therapeutics	+1.51%	+4.77%	+1.29%	+38.98%	+61.30%
ELAN Elanco Animal Health	-1.66%	-4.23%	+5.80%	-2.28%	+25.31%
OGN Organon & Co.	-0.58%	-0.65%	+0.40%	+1.56%	+32.03%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$210.68 +0.0%	$221.78	$112.90 ▼ $260.19	$11.03B	0.71	743,538 shs	73,270 shs
CORT Corcept Therapeutics	$115.65 0.0%	$105.69	$28.66 ▼ $126.38	$12.52B	0.45	1.48 million shs	84,991 shs
ELAN Elanco Animal Health	$23.23 -1.4%	$24.61	$18.22 ▼ $27.98	$11.59B	1.68	5.62 million shs	659,539 shs
OGN Organon & Co.	$13.66 -0.1%	$13.63	$5.69 ▼ $13.78	$3.59B	1.52	5.60 million shs	432,219 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	+1.35%	+0.34%	-4.64%	-17.00%	+67.59%
CORT Corcept Therapeutics	+1.51%	+4.77%	+1.29%	+38.98%	+61.30%
ELAN Elanco Animal Health	-1.66%	-4.23%	+5.80%	-2.28%	+25.31%
OGN Organon & Co.	-0.58%	-0.65%	+0.40%	+1.56%	+32.03%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	2.91	Moderate Buy	$267.60	27.02% Upside
CORT Corcept Therapeutics	2.50	Moderate Buy	$138.17	19.47% Upside
ELAN Elanco Animal Health	2.77	Moderate Buy	$29.09	25.26% Upside
OGN Organon & Co.	1.71	Reduce	$11.40	-16.51% Downside

Current Analyst Ratings Breakdown

Latest OGN, ELAN, CORT, and AXSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/8/2026	CORT Corcept Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
9/4/2026	ELAN Elanco Animal Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/31/2026	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$290.00
8/24/2026	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/24/2026	AXSM Axsome Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	CORT Corcept Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/20/2026	ELAN Elanco Animal Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/18/2026	CORT Corcept Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$164.00
8/18/2026	AXSM Axsome Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/12/2026	AXSM Axsome Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$306.00 ➝ $316.00
8/11/2026	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$304.00 ➝ $297.00

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$638.50M	17.28	N/A	N/A	$1.75 per share	120.39
CORT Corcept Therapeutics	$830.81M	15.05	$0.92 per share	126.26	$6.16 per share	18.77
ELAN Elanco Animal Health	$4.72B	2.46	$2.25 per share	10.33	$13.18 per share	1.76
OGN Organon & Co.	$6.22B	0.58	$5.74 per share	2.38	$2.89 per share	4.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$183.17M	-$3.75	N/A	51.89	N/A	-24.68%	-265.55%	-28.10%	11/2/2026 (Estimated)
CORT Corcept Therapeutics	$99.65M	$0.42	275.67	33.62	N/A	6.52%	8.26%	6.45%	11/4/2026 (Estimated)
ELAN Elanco Animal Health	-$232M	-$0.41	N/A	18.29	1.79	-3.96%	8.13%	3.99%	11/4/2026 (Estimated)
OGN Organon & Co.	$187M	$0.77	17.73	3.97	1.27	3.41%	88.97%	6.03%	11/9/2026 (Estimated)

Latest OGN, ELAN, CORT, and AXSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	AXSM Axsome Therapeutics	-$0.8921	-$0.99	-$0.0980	-$0.99	$221.11 million	$218.38 million
8/5/2026	Q2 2026	ELAN Elanco Animal Health	$0.2692	$0.34	+$0.0708	$0.11	$1.31 billion	$1.37 billion
7/29/2026	Q2 2026	CORT Corcept Therapeutics	$0.0243	$0.36	+$0.3357	$0.36	$221.15 million	$256.15 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
CORT Corcept Therapeutics	N/A	N/A	N/A	N/A	N/A
ELAN Elanco Animal Health	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.59%	N/A	10.39%	N/A

Latest OGN, ELAN, CORT, and AXSM Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/31/2026	OGN Organon & Co.	quarterly	$0.02	0.58%	8/14/2026	8/14/2026	9/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	1.52	1.43	1.34
CORT Corcept Therapeutics	N/A	2.86	2.77
ELAN Elanco Animal Health	0.58	2.05	1.10
OGN Organon & Co.	8.43	1.95	1.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
CORT Corcept Therapeutics	93.61%
ELAN Elanco Animal Health	97.48%
OGN Organon & Co.	77.43%

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	20.60%
CORT Corcept Therapeutics	20.70%
ELAN Elanco Animal Health	1.14%
OGN Organon & Co.	1.62%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	52.38 million	41.59 million	Optionable
CORT Corcept Therapeutics	730	108.10 million	85.72 million	Optionable
ELAN Elanco Animal Health	9,900	499.62 million	493.93 million	Optionable
OGN Organon & Co.	10,000	262.61 million	258.36 million	Not Optionable

OGN, ELAN, CORT, and AXSM Headlines

Recent News About These Companies

Orogen Royalties Acquires the Serpent Gold Project in Nevada

3 hours ago | accessnewswire.comA

WINTON GROUP Ltd Invests $6.90 Million in Organon & Co. $OGN

September 10 at 5:51 AM | marketbeat.com

434,200 Shares in Organon & Co. $OGN Acquired by Maven Securities LTD

September 9 at 5:51 AM | marketbeat.com

Public Employees Retirement System of Ohio Purchases New Position in Organon & Co. $OGN

September 9 at 4:41 AM | marketbeat.com

Carmignac Gestion Purchases Shares of 448,606 Organon & Co. $OGN

September 8 at 7:27 PM | marketbeat.com

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

September 8 at 10:01 AM | zacks.com

Organon & Co. (NYSE:OGN) Hits New 12-Month High - Should You Buy?

September 8 at 9:39 AM | marketbeat.com

Readystate Asset Management LP Makes New Investment in Organon & Co. $OGN

September 7 at 5:36 AM | marketbeat.com

Groupe la Francaise Acquires Shares of 775,382 Organon & Co. $OGN

September 7 at 4:23 AM | marketbeat.com

Absolute Gestao de Investimentos Ltda. Takes Position in Organon & Co. $OGN

September 7 at 3:11 AM | marketbeat.com

Contrasting RIV Capital (OTCMKTS:CNPOF) & Organon & Co. (NYSE:OGN)

September 5, 2026 | americanbankingnews.com

Organon & Co. (OGN) Stock Price, News, Quote & History - Yahoo Finance

September 4, 2026 | finance.yahoo.com

Organon & Co. (NYSE:OGN) Sets New 12-Month High - Time to Buy?

September 2, 2026 | americanbankingnews.com

Organon & Co. (OGN) Stock Earnings Call Transcripts - Yahoo Finance

September 1, 2026 | finance.yahoo.com

Organon & Co. (NYSE:OGN) Hits New 52-Week High - Should You Buy?

August 31, 2026 | marketbeat.com

Bank of America Corp DE Has $4.42 Million Stock Position in Organon & Co. $OGN

August 29, 2026 | marketbeat.com

2,670,523 Shares in Organon & Co. $OGN Bought by Kahn Brothers Group Inc.

August 28, 2026 | marketbeat.com

National Can-RISE Study to Help Close Critical Gaps in Menopause Research

August 27, 2026 | globenewswire.com

Organon & Co. (NYSE:OGN) Sets New 52-Week High - Still a Buy?

August 25, 2026 | marketbeat.com

Organon & Co. (NYSE:OGN) Given Average Rating of "Reduce" by Brokerages

August 24, 2026 | marketbeat.com

Organon & Co. (NYSE:OGN) Reaches New 12-Month High - Still a Buy?

August 19, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

OGN, ELAN, CORT, and AXSM Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$210.68 +0.05 (+0.02%)

As of 11:13 AM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Corcept Therapeutics NASDAQ:CORT

$115.65 -0.05 (-0.04%)

As of 11:13 AM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Elanco Animal Health NYSE:ELAN

$23.22 -0.33 (-1.38%)

As of 11:13 AM Eastern

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Organon & Co. NYSE:OGN

$13.66 -0.02 (-0.11%)

As of 11:13 AM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OGN, ELAN, CORT, and AXSM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OGN, ELAN, CORT, and AXSM Earnings

Compare Dividends

Latest OGN, ELAN, CORT, and AXSM Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OGN, ELAN, CORT, and AXSM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

OGN, ELAN, CORT, and AXSM Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

Corcept Therapeutics NASDAQ:CORT

Elanco Animal Health NYSE:ELAN

Organon & Co. NYSE:OGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools